Samsung signs biologics deal with Roche
October 25, 2013Manufacturing and Production Korea, Roche, Samsung
Roche is leaving nothing to chance in its pursuit of the biologics drug market, adding to its internal investment programme …
Sharon Hurley
October 25, 2013Medical Communications, Sales and Marketing Med Comms
Synergy Vision expands client services team to meet demand in UK and Ireland Award-winning medical communications agency Synergy Vision is …
Phoenix from Charnwood’s ashes
October 25, 2013Research and Development, Sales and Marketing AstraZeneca, Charnwood, medilink
The shuttering of AstraZeneca’s R&D site at Charnwood in Leicestershire has had a positive effect on the region’s life sciences …
NICE ‘yes’ to Lucentis – with price cut
October 25, 2013Sales and Marketing Dillon, Lucentis, NICE, Novartis
A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …
Banker joins Lilly Board
October 25, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing jackson tai, lilly
Eli Lilly has appointed ex-investment banker Jackson Tai to its Board to serve on the Audit and Finance Committee from …
LEO Pharma to release clinical trial data
October 24, 2013Research and Development, Sales and Marketing Goldacre, LEO Pharma, all trials, transparency
LEO Pharma has announced that it will start releasing clinical trial data from studies dating back to almost 25 years …
IBM tests cancer diagnostic
October 24, 2013Medical Communications, Research and Development, Sales and Marketing Cancer, Zurich, ibm
IT giant IBM has teamed up with the University Hospital in Zurich to research a new oncology diagnostic test, in …
bmore creative appoints strategy director
October 24, 2013Medical Communications, Sales and Marketing bmore creative
Design, advertising and digital agency bmore creative has appointed Paul Haley to join its management team as a strategy director.Having …
Corruption probe hits GSK
October 24, 2013Sales and Marketing China, GSK, Q3, corruption
The fallout from corruption investigations in China has hit GlaxoSmithKline, which announced third quarter sales in the country were down …
Open access splits researchers
October 24, 2013Medical Communications, Research and Development, Sales and Marketing BMJ, open access, publishing, research
Small medical research charities are worried that the extra costs of open access publishing will have a significant impact on …
Horizon Discovery chairman steps down from Board
October 24, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing evans, horizon
Research tools firm Horizon Discovery has confirmed that David Evans has stepped down as chairman of its Board. Dr Ian …
Novartis sees profit slip
October 23, 2013Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya
Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …
Sanofi launches ‘Monster Manor’ diabetes app
October 23, 2013Medical Communications Gamification, Sanofi, diabetes, monster manor
Sanofi has launched a new healthcare app called Monster Manor to help children with type 1 diabetes better manage their …
Indian pharma exports ‘set for 20% growth’ to 2018
October 23, 2013Manufacturing and Production API, CPhI, GMP, India, growth
Representatives of India’s pharma sector pledged to meet the government’s target of raising exports to $25 billion by 2016, as …
Reckitt Benckiser may shed pharma unit
October 23, 2013Sales and Marketing Reckitt Benckiser Pharmaceuticals, rbp, suboxone
Reckitt Benckiser Pharmaceuticals is considering selling its pharma unit within the next year after the recent loss of its biggest …
HGS founders join IMS Health team
October 23, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HGS, IMS Health, mcfarlane
Healthcare services firm IMS Health has appointed HGS Europe founders Graeme McFarlane and Angela McFarlane (pictured) to its UK team.
NICE ‘yes’ for Jetrea
October 23, 2013Sales and Marketing Jetrea, NHS, NICE, eye
Jetrea has completed its seemingly inexorable journey to NHS use in England and Wales for a rare eye condition following …
AZ begins late-stage trial of new cancer drug
October 22, 2013Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib
AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …
US regulator ponders Arzerra
October 22, 2013Sales and Marketing Arzerra, CLL, FDA, GSK
GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the FDA as a first-line treatment for chronic lymphocytic …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
